Sewoonmedical Co., Ltd.

As of March 31, 2026, Sewoonmedical Co., Ltd. carries a market capitalization of 106.50B, placing it among publicly traded companies globally. Its enterprise value stands at 10.86B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of March 31, 2026, Sewoonmedical Co., Ltd. has 42.18M shares outstanding.

As of March 31, 2026, Sewoonmedical Co., Ltd. trades at a trailing price-to-earnings ratio of 8.51. The price-to-sales ratio is 1.66, and the price-to-book ratio stands at 0.70.

As of March 31, 2026, Sewoonmedical Co., Ltd. trades at an EV/EBITDA multiple of 0.65 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 0.17 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 0.81 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. Sewoonmedical Co., Ltd. trades at an EV/FCF ratio of 0.69, comparing the total takeover cost of the business to the cash it actually generates for all capital providers. These enterprise value multiples are built on an enterprise value of 10.86B versus a market cap of 106.50B, with the gap driven by net debt and cash on the balance sheet.

As of March 31, 2026, Sewoonmedical Co., Ltd. maintains a current ratio of 12.66, meaning it holds 12.7x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 0.52, indicating moderate leverage, while an interest coverage ratio of 510.21 demonstrates strong ability to service its debt obligations.

Over the twelve months ended March 31, 2026, Sewoonmedical Co., Ltd. posted a return on equity (ROE) of 8.44, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 6.98 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 7.73, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 7.99, useful for judging operating efficiency across full business cycles. The company generates approximately 343.02M in revenue per employee across its workforce of 188.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 2.29 indicates how many times Sewoonmedical Co., Ltd. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended March 31, 2026, Sewoonmedical Co., Ltd. recorded 3.05B in income tax expense. That works out to an effective tax rate of 19.00, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 16.03B, leaving 12.61B in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 23, 2026, Sewoonmedical Co., Ltd.'s stock has declined approximately 5.99% over the past 52 weeks. The 50-day moving average sits at 2,363.30, while the 200-day moving average is 2,436.90.

Over the twelve months ended March 31, 2026, Sewoonmedical Co., Ltd. generated 64.49B in revenue and converted that into 12.61B in net income, yielding earnings per share of 305.53. EBITDA reached 16.59B, while operating income came in at 13.33B.

As of March 31, 2026, Sewoonmedical Co., Ltd. holds 99.85B in cash and equivalents against 816.55M in total debt, resulting in a net debt position of -99.85B. Total book value stands at 152.85B, with working capital of 121.52B providing operational flexibility.

Sewoonmedical Co., Ltd. produced 17.15B in operating cash flow over the twelve months ended March 31, 2026. After subtracting -1.49B in capital expenditures, free cash flow totaled 15.65B - equivalent to 368.31 per share.

Over the twelve months ended March 31, 2026, Sewoonmedical Co., Ltd. posted a gross margin of 37.72, reflecting its pricing power and cost economics. The operating margin of 20.67 and net profit margin of 19.56 provide insight into operational efficiency.

Over the twelve months ended March 31, 2026, Sewoonmedical Co., Ltd. paid dividends of - - per share. The dividend payout ratio of - - indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Free cash flow yield stands at 14.59, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield reaches 5.48, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Sewoonmedical Co., Ltd. shareholders.

Sewoonmedical Co., Ltd.'s most recent stock split took place on September 24, 2009 with a 1:2 split ratio.

As of March 31, 2026, Sewoonmedical Co., Ltd. has an Altman Z-Score of 8.52, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.